DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

MK-2206 for Recurrent Malignant Glioma

Phase 2

Withdrawn

Conditions: Malignant Glioma

Interventions: Drug: MK-2206

First Posted Date: 2010-11-29

Last Posted Date: 2016-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01249105

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States

and more 2 locations

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

Not Applicable

Completed

Conditions: Esophageal Cancer

Interventions: Drug: 3'-deoxy-3'-(18) F-fluorothymidine

First Posted Date: 2010-11-18

Last Posted Date: 2017-05-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01243619

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Phase 2

Terminated

Conditions: Chronic Graft-versus-host Disease

Interventions: Drug: Alefacept

First Posted Date: 2010-10-22

Last Posted Date: 2013-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT01226420

Locations: 🇺🇸
Fred Hutch Cancer Research Center, Seattle, Washington, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: NSCLC
Non-small Cell Lung Cancer
Lung Cancer

Interventions: Radiation: Stereotactic boost
Radiation: Conventional RT
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2010-10-18

Last Posted Date: 2015-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01222572

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Human Papilloma Virus

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: 5-FU
Radiation: IMRT
Drug: cetuximab
Drug: carboplatin

First Posted Date: 2010-10-15

Last Posted Date: 2017-12-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01221753

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease

Completed

Conditions: Chronic Graft vs Host Disease
cGVHD
Graft vs Host Disease

First Posted Date: 2010-10-15

Last Posted Date: 2015-03-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT01221766

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Phase 2

Completed

Conditions: Ocular Melanoma

Interventions: Drug: STA-9090

First Posted Date: 2010-09-13

Last Posted Date: 2018-10-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT01200238

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2

Active, not recruiting

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: bevacizumab
Drug: trastuzumab
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2010-08-31

Last Posted Date: 2024-10-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01191697

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: trastuzumab
Drug: vinorelbine

First Posted Date: 2010-08-20

Last Posted Date: 2019-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT01185509

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1

Completed

Conditions: Solid Tumor
Kidney Cancer

Interventions: Drug: pazopanib
Drug: everolimus

First Posted Date: 2010-08-18

Last Posted Date: 2019-10-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01184326

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy